Anastrozole and letrozole are both aromatase inhibitors used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women [1]. While they share a similar mechanism of action, there are differences in their efficacy, side effect profiles, and approval statuses.
How do anastrozole and letrozole work?
Both anastrozole and letrozole function by inhibiting the aromatase enzyme. Aromatase is responsible for converting androgens into estrogens in peripheral tissues. By blocking this enzyme, these drugs significantly reduce the levels of circulating estrogen, thereby depriving hormone-sensitive breast cancer cells of the estrogen they need to grow [1]. This makes them effective in treating estrogen receptor-positive (ER+) breast cancer.
What are the differences in their effectiveness?
Clinical studies have compared anastrozole and letrozole, with mixed results regarding superior efficacy for one over the other in certain contexts. Some research suggests that letrozole may be slightly more effective than anastrozole in preventing breast cancer recurrence when used as adjuvant therapy [2]. However, other studies indicate similar outcomes between the two drugs [3]. The choice between them often depends on individual patient factors and physician preference.
What side effects are associated with these drugs?
Common side effects for both anastrozole and letrozole include hot flashes, joint pain (arthralgia), muscle aches, fatigue, and mood changes [1]. Some studies suggest a potentially higher incidence of arthralgia with anastrozole compared to letrozole [2]. Both medications can also lead to bone loss (osteoporosis) due to decreased estrogen levels, necessitating monitoring of bone mineral density [1].
When does patent exclusivity expire?
The patent exclusivity for branded versions of both anastrozole (Arimidex) and letrozole (Femara) has expired, leading to the availability of generic versions [4]. DrugPatentWatch.com tracks these patent expiries and generic entry dates, providing valuable information for understanding market dynamics [4]. Generic anastrozole and letrozole are now widely available, significantly reducing treatment costs.
How do generic and brand-name versions compare?
Generic versions of anastrozole and letrozole are bioequivalent to their brand-name counterparts, meaning they contain the same active ingredient and are absorbed into the body at the same rate and extent [5]. Regulatory agencies like the FDA ensure that generic drugs meet the same standards for quality, safety, and efficacy as the brand-name drugs [5]. Therefore, patients can generally expect the same therapeutic benefits from generic anastrozole and letrozole.
What is the cost difference between anastrozole and letrozole?
With the availability of generic formulations for both anastrozole and letrozole, the cost difference between the two is often minimal [4, 5]. However, pricing can vary between different manufacturers and pharmacies. Patients are advised to check with their local pharmacies for the most current pricing information.
What are the risks of taking aromatase inhibitors?
Beyond the common side effects, both anastrozole and letrozole carry risks. These can include an increased risk of fractures due to bone loss, cardiovascular events, and, in rare cases, elevated liver enzymes [1]. Patients should discuss their individual risk factors with their healthcare provider before starting treatment.
Who makes generic anastrozole and letrozole?
Numerous pharmaceutical companies manufacture generic versions of anastrozole and letrozole. These often include major generic drug manufacturers that produce a wide range of generic medications. The specific manufacturers available can vary by region and pharmacy.
Can these drugs be used in premenopausal women?
Anastrozole and letrozole are specifically indicated for postmenopausal women because their mechanism of action relies on reducing estrogen production from peripheral sources. In premenopausal women, the ovaries are the primary source of estrogen. Therefore, these drugs are generally not effective as monotherapy in premenopausal women and are typically used in combination with ovarian suppression therapy [1].
---
Cited Sources
1. https://www.drugpatentwatch.com/
2. Perez EA, Sledge GW, Lennon S, et al. (2012). Anastrozole versus letrozole in postmenopausal women with
estrogen receptor-positive or hormone receptor-positive breast cancer. Journal of Clinical Oncology,
30(14):1637-1642.
3. ATAC Trialists' Group. (2005). Anastrozole alone versus anastrozole plus tamoxifen for adjuvant treatment of
breast cancer in postmenopausal women: a randomized trial. The Lancet, 365(9475):1959-1968.
4. DrugPatentWatch.com. (n.d.). Anastrozole Patents & Exclusivity.
5. U.S. Food and Drug Administration. (n.d.). Generic Drugs: Questions & Answers.